Publications by authors named "C Stellbrink"
Article Synopsis
- The study investigates the effects of resting heart rate (RHR) on patients with heart failure who received implantable cardioverter-defibrillators (ICDs) or cardiac resynchronization therapy-defibrillators (CRT-Ds), specifically examining RHRs above and below 70 bpm.
- A total of 1589 patients were analyzed, and results showed that one-year all-cause mortality and major cardiovascular events were similar between those with RHR ≤ 70 bpm and > 70 bpm.
- However, patients with RHR > 70 bpm had higher rates of all-cause hospital admissions, mainly due to non-cardiovascular events, indicating potential increased risks associated with a higher RHR.
Article Synopsis
- The OmniaSecure defibrillation lead is a new, small-diameter lead aimed at improving targeted placement for better long-term performance in implantable cardioverter-defibrillators.
- The LEADR pivotal clinical trial involved 643 patients and showed that the lead was successfully placed in the correct position for 99.5% of participants, with a 97.5% success rate for defibrillation at implantation.
- The trial results indicated high safety and efficacy, with a 97.1% freedom from major complications and no lead fractures over an average follow-up of 12.7 months.
Impact of atrial fibrillation on 1-year outcome in patients with implantable cardioverter defibrillator or cardiac resynchronization therapy with defibrillator: results from the German DEVICE Registry.
J Thorac Dis
March 2024
Background: Atrial fibrillation (AF) is a cardiac arrhythmia frequently documented in patients requiring implantable cardioverter defibrillators (ICDs) and/or cardiac resynchronization therapy with defibrillator (CRT-D). Patients with diagnosed AF at the point of ICD or CRT-D implantation may have an impaired follow-up outcome.
Methods: The German DEVICE I-II registry is a nationwide prospective multicentre database of patients implanted with ICD and CRT-D with clinical follow-up data.
[History of cardiac resynchronization therapy : 30 years of electrotherapeutic management for heart failure].
Herzschrittmacherther Elektrophysiol
March 2024
The first permanent biventricular pacing system was implanted more than 30 years ago. In this article, the historical development of cardiac resynchronization therapy (CRT), starting with the pathophysiological concept, followed by the initial "proof of concept" studies and finally the large prospective-randomized studies that led to the implementation of CRT in heart failure guidelines, is outlined. Since the establishment of CRT, both an expansion of indications, e.
View Article and Find Full Text PDFBackground: Due to suspected pro-arrhythmic effects and increased mortality associated with class-IC antiarrhythmic drugs (AADs) in previous trials, AAD therapy in structural heart disease (SHD) is mainly restricted to amiodarone. In the presence of diagnostic and therapeutic advancements in cardiovascular medicine, it remains unclear if previous studies adequately reflect contemporary patients. In clinical practice, class-IC-AADs are occasionally used in individual cases, particularly in patients with an implantable cardioverter defibrillator (ICD).
View Article and Find Full Text PDF